Biotech spin­out grabs $46M round, jumps straight in­to PhI­II with a drug/de­vice com­bo for rare lung con­di­tion

The Ger­man aerosol ther­a­py com­pa­ny PARI Phar­ma­ceu­ti­cals is spin­ning out a Phase III ef­fort to de­vel­op a drug/de­vice com­bo that match­es an in­haled for­mu­la­tion of an im­muno­sup­pres­sant with a re­mote­ly mon­i­tored de­liv­ery de­vice to treat a rare lung con­di­tion. And it’s re­cruit­ed a trio of Eu­ro­pean ven­ture groups, in­clud­ing Sofinno­va Part­ners in Paris, to back a €43.5 mil­lion (about $46 mil­lion) round to boot it up to reg­u­la­tors on both sides of the At­lantic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER